387 results on '"Jerkeman, M"'
Search Results
2. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
4. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
5. Primary central nervous system lymphomas:EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
6. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
7. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
8. 2667: Clinic-wide PROMs of all radiotherapy patients: a pilot study
9. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
10. SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA
11. A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
12. Emerging role of SOX11 in mantle cell lymphoma
13. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
14. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
15. Targeting of B‐cell receptor signalling in B‐cell malignancies
16. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study
17. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA
18. P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
19. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
20. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
21. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL
22. HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY
23. Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis
24. Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).
25. Myocardial infarction in diffuse large B‐cell lymphoma patients – a population‐based matched cohort study
26. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study
27. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: A nordic lymphoma group trial
28. PPM3 Cost-Effectiveness of Axicabtagene Ciloleucel (AXI-CEL) VS Standard of Care for Adult Patients with Relapsed or Refractory Diffuse Large B-CELL Lymphoma in Sweden, Norway, Finland, and Denmark
29. Erratum to: Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study
30. Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition
31. Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study
32. ESMO Guidelines: Cancer patient management during the COVID-19 pandemic
33. Genes associated with tumor microenvironment are important predictors of response to chemotherapy in diffuse large B-cell lymphoma: 178
34. Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis
35. Monotherapy with the anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disease (PTLD) results of a multicentre phase II study: 221
36. Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women from the European Prospective Investigation into Cancer and Nutrition
37. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition
38. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas
39. THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS
40. EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME
41. EVOLUTION OF CLONAL HEMATOPOIESIS IN MANTLE CELL LYMPHOMA PATIENTS BEFORE, DURING, AND AFTER INDUCTION CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION
42. YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS
43. PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES
44. SERUM BIOMARKERS ARE ASSOCIATED WITH TREATMENT RESPONSE IN RELAPSED MANTLE CELL LYMPHOMA
45. Bacteremic and non-bacteremic febrile urinary tract infection — a review of 168 hospital-treated patients
46. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
47. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B‐cell lymphoma: a Swedish lymphoma register study
48. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study
49. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma : a Nordic Lymphoma Group Population-based Study
50. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma:a Nordic Lymphoma Group Population-based Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.